SIS Shulov Innovative Science

Company Overview

Snapshot

Founded in January 1985 by Aviv Marx and Ophir Shahaf, SIS Shulov Innovative Science operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on advancing its novel pharmaceutical entities. SIS Shulov Innovative Science is actively conducting a Phase II clinical study for Atopic Dermatitis in Israel, demonstrating ongoing clinical development.

Business overview

SIS Shulov Innovative Science is an advanced clinical-stage biopharmaceutical company developing New Chemical Entities (NCEs) for various therapeutic applications. Its core technology involves short synthetic peptides, branded as ZEP-3 and ZEP-4, which exhibit combined anti-inflammatory, anti-viral, and analgesic properties. The company focuses on dermatology and other indications, serving markets in the United States and Israel within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

What is SIS Shulov Innovative Science's primary focus?

SIS Shulov Innovative Science is primarily focused on developing New Chemical Entities (NCEs), specifically short synthetic peptides, for various therapeutic uses, particularly in dermatology.

What clinical trials is SIS Shulov Innovative Science currently conducting?

SIS Shulov Innovative Science has completed a Phase II clinical study for Herpes Labialis and is conducting a Phase II clinical study for Atopic Dermatitis across nine clinical sites in Israel.

What are the lead compounds developed by SIS Shulov Innovative Science?

The lead compounds developed by SIS Shulov Innovative Science are short synthetic peptides branded as ZEP-3 and ZEP-4, which possess unique biological activity for a wide range of clinical indications.

Which regulatory body has SIS Shulov Innovative Science approached for its lead compound?

SIS Shulov Innovative Science has approached the FDA in preparation for a pre-IND meeting to secure an IND submission for an advanced Phase III clinical trial in Herpes Labialis patients in the US.

What additional clinical indications is SIS Shulov Innovative Science developing?

SIS Shulov Innovative Science is developing additional clinical indications including Herpes Zoster, Genital Herpes, Burns, and Lung Inflammation, with pre-clinical work completed and readiness to start Phase I/II studies for each.